EU grants approval for Gilead's Viread in hepatitis Bby Bryan DeBusk
Gilead announced that the European Commission granted marketing authorisation for once-daily Viread (tenofovir disoproxil fumarate) as a treatment for chronic hepatitis B.
The drugmaker noted that the decision was based primarily on data from two ongoing Phase III trials examining the safety, tolerability and efficacy of the drug compared with Gilead's Hepsera in patients with the disease.
The company also indicated that applications are pending in the US, Canada and Australia for the use of Viread in chronic hepatitis B
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment